Findings

What do systematic reviews say?

188 questions · 193 findings · 30 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 54 · 28%GRADE not reported 23 · 11.9%Very low 50 · 25.9%Low 47 · 24.4%Moderate 15 · 7.8%High 4 · 2.1%

INTENSIVE CASE MANAGEMENT vs usual care

Relapse · people with severe mental disorders

The review found no eligible studies for this question.

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

INTENSIVE CASE MANAGEMENT vs usual care

Leaving the study early · people with severe mental disorders

Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with standard care (low certainty).

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
RR 0.68 [0.58, 0.79]
13 studies · 1798 participants
Low

INTENSIVE CASE MANAGEMENT vs usual care

Social functioning: 2. Employment status (various measurements) ‐ by long term ‐ not employed at the end of the trial · people with severe mental disorders

It is very uncertain whether intensive Case Management changes social functioning: 2. Employment status (various measurements) ‐ by… compared with standard care (very low certainty).

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
RR 0.7 [0.49, 1]
4 studies · 1129 participants
Very low

INTENSIVE CASE MANAGEMENT vs usual care

Mental state: No clinically important improvement · people with severe mental disorders

The review found no eligible studies for this question.

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

INTENSIVE CASE MANAGEMENT vs NON‐INTENSIVE CASE MANAGEMENT

Service use: 3b. Average number of admissions (skewed data ‐ sample size ≧ 200) ‐ by long term · people with severe mental disorders

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 678 participants
Moderate

INTENSIVE CASE MANAGEMENT vs NON‐INTENSIVE CASE MANAGEMENT

Adverse event: 1b. Death ‐ suicide ‐ by long term · people with severe mental disorders

Intensive Case Management showed no clear difference in adverse event: 1b. Death ‐ suicide ‐ by long term compared with non‐Intensive Case Management (low certainty).

1 finding from 1 review

Intensive case management for severe mental illness 2017 · Cochrane Headline outcomes only
RR 0.88 [0.27, 2.84]
3 studies · 1152 participants
Low

Individual TF‐CBT vs Brief PTSD psychoeducation

Quality of life: 1. General quality of life · Adults with co‐morbid PTSD and SMI

1 finding from 1 review

Psychological interventions for post‐traumatic stress disorder (PTSD) in people with severe mental illness 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

WENDAN DECOCTION vs antipsychotics

Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia

1 finding from 1 review

Wendan decoction (Traditional Chinese medicine) for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs STANDARD DOSE ANTIPSYCHOTICS

Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia

1 finding from 1 review

Wendan decoction (Traditional Chinese medicine) for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs STANDARD DOSE ANTIPSYCHOTICS

Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia

1 finding from 1 review

Wendan decoction (Traditional Chinese medicine) for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

WENDAN DECOCTION vs placebo or no treatment

Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia

1 finding from 1 review

Wendan decoction (Traditional Chinese medicine) for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs placebo

Global state: Relapse ‐ long term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 10.27 [0.59, 180.05]
1 study · 85 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Weight gain · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.56, 3.17]
1 study · 85 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.34 [1.13, 1.58]
1 study · 369 participants
Very low

RISPERIDONE DEPOT vs RISPERIDONE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs placebo

Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs QUETIAPINE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Mental state ‐ improvement · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.74, 0.95]
1 study · 666 participants
Moderate